ReviewFrontiers in immunology2026
Cuproptosis and anti-tumor immunity: bidirectional regulation, controversies, and translational prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis is a copper-dependent form of regulated cell death driven by copper binding to lipoylated tricarboxylic acid (TCA) cycle proteins. This interaction triggers aberrant protein aggregation, Fe-S cluster protein degradation, and mitochondrial proteotoxic stress, and its unique metabolic dependency distinguishes cuproptosis from apoptosis and ferroptosis. This review examines the bidirectional regulation between cuproptosis and anti-tumor immunity. Cuproptosis can promote dendritic cell maturation and CD8+ T cell-mediated immunity through immunogenic cell death (ICD), damage-associated molecular pattern release, and cGAS-STING pathway activation. Activated CD8+ T cells may in turn enhance tumor cell cuproptosis sensitivity via IFN-γ-STAT1-IRF1-driven FDX1 upregulation, forming a positive feedback loop. Conversely, direct copper toxicity toward T cells and NK cells, spatial heterogeneity of intratumoral copper distribution, and potential immunosuppressive cytokine release may counterbalance these immunostimulatory effects. We outline core controversies regarding the universality of cuproptosis immunogenicity, the immune activation window of copper ions, and the clinical utility of cuproptosis biomarkers. Translational strategies including copper ionophore-immunotherapy combinations, copper-based nano-delivery systems, and copper metabolism-based patient stratification are discussed. The cuproptosis-immunity intersection remains at an early stage; key mechanistic findings require independent validation before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.